BEDFORD, Mass., Nov. 29, 2011 /PRNewswire/ — Instrumentation
Laboratory (IL) today announced the release of the new HemosIL von
Willebrand Factor Ristocetin Cofactor Activity (VWF: RCo) assay as
a European CE IVD Mark product under the European Directive on
in vitro Diagnostic Medical Devices.  It will be
commercialized in Europe and other international regions. 
This new, fully automated VWF: RCo assay is for use on the ACL
TOP® Family of Hemostasis Testing Systems. Together with other
HemosIL reagents (HemosIL VWF Antigen, HemosIL VWF Activity, and
HemosIL FVIII), it aids in the diagnosis and monitoring of von
Willebrand Disease (VWD). 

(Logo:  http://photos.prnewswire.com/prnh/20100803/NE44435LOGO )

Based on new proprietary technology, the assay represents an
innovative approach to VWD testing. Demonstrating excellent
agreement with existing ristocetin-platelet-based tests, the
HemosIL VWF: RCo assay eliminates platelet-associated
variability.  The result is superior precision. 
Additionally, variability associated with human interpretation,
common with manual testing methods, is eliminated.  Moreover,
because the assay is automated, liquid and ready-to-use, results
are available in minutes and on-demand, 24/7. 

“This important new addition to our portfolio of VWF assays will
help ensure early diagnosis and proper treatment for patients,”
said Remo Tazzi, Director, Hemostasis Marketing at IL.  “By
simplifying and automating a complex procedure, the HemosIL VWF:
RCo assay marks a significant improvement in not only the
turnaround time for results, but also in accuracy and
precision.  It is a perfect example of our commitment to
providing specialized solutions for disease-state management.”

About von Willebrand Disease

VWD is the most common inherited blood disorder, occurring in
app

‘/>”/>

SOURCE